Anesthesia

A variable-bypass vaporizer splits fresh gas flow between a bypass channel (never touches liquid) and a vaporizing chamber (saturated with agent vapor), recombining so the output equals the dial-set % regardless of FGF, within the design range (0.2-15 L/min).

FGF enters -> splits at splitting valve: (1) bypass flow (majority) and (2) vaporizing chamber flow (saturated over wicks) -> streams recombine downstream -> dial controls splitting ratio.

• Wick system increases surface area for evaporation
• Agent-specific keyed filling systems (Tec-fill, Saf-T-fill) prevent cross-filling
• Concentration-calibrated (not flow-calibrated)
• Located outside the circle system (VOC), interlocked against simultaneous use of >1 vaporizer

As liquid vaporizes it absorbs latent heat -> chamber cools -> SVP falls -> output would decrease. Compensation:

Flow compensation: modern vaporizers use flow-dependent, non-linear splitting ratios to maintain accurate output across 0.2-15 L/min.

• Tilting/overturning: liquid can spill into bypass channel -> unpredictable concentrated bolus
• Overfilling beyond max mark: same hazard
• Underfilling: inadequate wick saturation -> falsely low output, awareness risk
• Post-tilt protocol: take out of service, flush at high FGF/high setting with chamber isolated before reuse
• Desflurane exception: needs an electrically heated, pressurized vaporizer (Tec 6), not simple variable-bypass

Explain temperature compensation mechanistically (bimetallic strip + thermal mass). Tie pumping effect explicitly to IPPV and differential gas compressibility.

Mapleson systems are valveless (semi-open) circuits classified A-F by relative position of the fresh gas inlet, reservoir bag, and APL valve. Efficiency at preventing rebreathing differs dramatically between spontaneous and controlled ventilation.

Mnemonic: efficiency for spontaneous ventilation A > DFE > CB. For controlled ventilation: DFE > BC > A (reverse order).

Why preferred in pediatrics: lightweight, minimal apparatus dead space, very low resistance, direct feel/observation of compliance.

State the mnemonic ranking explicitly and explain the mechanism for Mapleson A. Always volunteer the Bain inner-tube disconnection hazard.

Dexmedetomidine is a highly selective alpha2-adrenergic agonist (alpha2:alpha1 ~1620:1) that produces sedation by hijacking the brain's natural sleep pathway (locus coeruleus -> VLPO) rather than acting on GABA receptors - explaining its ""cooperative/arousable sedation"" profile and lack of significant respiratory depression.

• Target: alpha2-adrenoceptors (alpha2A/2B/2C), Gi-coupled, lower cAMP
• alpha2A: sedation, analgesia, sympatholysis (locus coeruleus, spinal cord)
• alpha2B: initial vasoconstrictive hypertensive response, shivering suppression
• alpha2C: cognitive/sensory modulation, startle response
• Presynaptic: inhibits NE release; Postsynaptic: hyperpolarizes locus coeruleus neurons

Binds alpha2A in locus coeruleus -> hyperpolarization, lower NE release -> disinhibits ventrolateral preoptic nucleus (VLPO) -> VLPO releases GABA/galanin -> suppresses arousal centers -> mimics natural non-REM (stage 2) sleep. This differs fundamentally from GABAergic agents (propofol/benzodiazepines) which directly potentiate GABA-A receptors - explaining easy arousability. Analgesic mechanism: dorsal horn alpha2 agonism inhibits substance P, opioid-receptor-independent.

Hepatic impairment significantly prolongs clearance (dose reduction needed); renal impairment has minimal effect on parent drug.

Bradycardia common (caution with beta-blockers/heart block). Reduces MAC and blunts laryngoscopy response. Does NOT cause significant myocardial depression.

• Analgesic/opioid-sparing
• Anti-shivering (alpha2B, resets hypothalamic threshold)
• Reduces emergence delirium and PACU agitation
• Diuresis (inhibits ADH)
• No effect on seizure threshold - useful during neurophysiological monitoring

Name the locus coeruleus -> VLPO pathway explicitly. Describe the biphasic CV response with receptor basis. State respiratory drive preservation and tie to awake fiberoptic intubation.

The supraclavicular approach blocks the plexus at the trunks/divisions - the most compact point, lateral and superficial to the subclavian artery just above the first rib - the ""spinal of the arm"": dense, rapid anesthesia of the entire upper limb from one injection.

Roots (C5-T1) emerge between scalenus anterior/medius -> Trunks (upper C5-6, middle C7, lower C8-T1) at interscalene groove -> cross first rib, split into Divisions behind clavicle -> reorganize into Cords (lateral/posterior/medial) in axilla -> Terminal Branches. Mnemonic: Roots, Trunks, Divisions, Cords, Branches.

• Trunks lie superior/lateral/posterior to subclavian artery - ""bunch of grapes""/""traffic light"" pattern
• Subclavian artery anterior to first rib and pleura/lung apex
• First rib and pleura lie deep/medial to artery - basis of historical pneumothorax risk
• Suprascapular nerve often already branched off
• Phrenic nerve on anterior scalenus anterior, medial/anterior to plexus

• Position: supine, head turned away, arm adducted
• Probe: 10-15 MHz linear, supraclavicular fossa, angled caudally
• Identify subclavian artery, then plexus cluster, then first rib/pleura (confirm lung sliding)
• Needle: in-plane, lateral to medial (preferred)
• Target the corner pocket first for lower trunk/ulnar coverage
• Inject incrementally 3-5 mL aliquots with intermittent aspiration, watch halo sign
• Volume: 20-30 mL (0.5% ropivacaine or 0.375-0.5% bupivacaine +/- dexamethasone)
• Confirm spread around all trunk components before withdrawing

Draw/describe the ""bunch of grapes"" appearance relative to the subclavian artery. Mention the corner-pocket strategy and the ~50% phrenic nerve incidence figure.

HPV is a unique, intrinsic, locally-mediated pulmonary vascular reflex - opposite of systemic circulation where hypoxia causes vasodilation. By diverting flow away from poorly-ventilated alveoli, HPV optimizes V/Q matching and is the single most important mechanism limiting hypoxemia during OLV.

Alveolar hypoxia (primary trigger) -> sensed by pulmonary vascular smooth muscle cells themselves -> inhibition of Kv channels -> depolarization -> Ca2+ influx/release -> smooth muscle contraction -> vasoconstriction of small pulmonary arterioles -> blood diverted to better-ventilated regions.

• Site: pre-capillary arterioles (200-500 um), not larger conducting arteries
• Biphasic: immediate phase (minutes) + sustained phase (hours)
• Regional/local, functions independently in each segment - persists in denervated/transplanted lungs
• Can reduce flow to a hypoxic region by up to 50%

• Hypoxemia is the principal concern - non-ventilated lung still gets ~20-30% CO as shunt
• V/Q mismatch: non-dependent lung becomes a pure shunt unit
• Time course: HPV reduces non-ventilated lung flow from ~40% to ~20-25% within 20-30 minutes

State HPV is local/intrinsic (persists in denervated lungs). List 4-5 blunting factors with mechanism and connect back to OLV hypoxemia troubleshooting.

LAST occurs because LAs block voltage-gated Na+ channels non-selectively - at sufficient systemic concentration they block CNS and cardiac Na+ channels. Bupivacaine is disproportionately cardiotoxic due to ""fast-in, slow-out"" kinetics; CNS toxicity classically precedes cardiac toxicity except with bupivacaine.

• Primary: Na+ channel blockade in excitable tissue at toxic systemic concentrations
• CNS: preferentially blocks inhibitory interneurons first -> excitatory phase -> then global depression
• Cardiac: slows phase 0 depolarization -> conduction slowing -> re-entrant arrhythmias; bupivacaine also inhibits mitochondrial fatty acid metabolism
• ""Fast-in, slow-out"" (bupivacaine): rapid binding during systole, slow dissociation during diastole -> cumulative use-dependent block at normal heart rates -> disproportionate cardiotoxicity

Bupivacaine cardiac arrest is classically refractory to standard ACLS - lipid emulsion is a specific antidote; prolonged resuscitation (up to an hour+) may succeed.

Concurrent measures: stop injecting LA, call for help, get lipid kit; 100% O2; benzodiazepines for seizures (avoid propofol if unstable); reduce initial epinephrine to <=1 mcg/kg, avoid vasopressin/CCBs/beta-blockers, amiodarone preferred for VT; prepare for prolonged resuscitation (>1h), consider CPB early; monitor 4-6h post-event (2h if CNS-only).

Quote the lipid protocol exactly (1.5 mL/kg bolus, 0.25 mL/kg/min infusion, max 12 mL/kg). Mention 40-60% atypical presentations and reduced epinephrine dosing.

This patient combines two independent high-risk factors: severe systolic heart failure (EF 25%) requiring meticulous hemodynamic management, and a CIED requiring EMI mitigation, especially with monopolar electrocautery near the upper abdomen. Manage both simultaneously.

Cardiac optimization: assess NYHA class/recent decompensation; review recent echo; continue beta-blockers, hold ACE-I/ARB morning of surgery; correct K+/Mg2+; ECG, BNP/troponin baseline; involve high-risk team early given urgent status.

Anesthetic technique: GA typically required (open surgery). Goal: hemodynamic stability, avoid myocardial depression - slow titrated induction with etomidate or careful low-dose propofol, high-dose opioid. Avoid ketamine if active ischemia a concern. Maintenance: low-dose volatile + opioid, or careful TIVA. Avoid both tachycardia/excess afterload and excessive bradycardia/hypotension.

• ICU/HDU admission for continuous monitoring
• Device re-interrogation by cardiology - confirm function, restore original settings
• Judicious fluid management, inotropic support if needed (dobutamine/milrinone)
• Multimodal analgesia (rectus sheath/TAP blocks) to minimize opioid/sympathetic swings
• Resume cardiac medications as tolerated; monitor for arrhythmia/ischemia/decompensation

Structure the answer around the two parallel risk domains (cardiomyopathy + CIED/EMI). State the surgical-site rule (above umbilicus = higher EMI risk) and mention external pacing/defib availability.

BCIS results from embolic phenomena (fat, marrow, cement, air forced into venous circulation during pressurization/insertion) plus the direct vasoactive/cardiodepressant effects of circulating methylmethacrylate monomer - spectrum from transient hypoxemia to catastrophic collapse, most dramatic at cementing/insertion.

Reaming + cement pressurization -> marrow fat, debris, air, monomer forced into venous sinusoids -> embolization to lungs -> (1) mechanical obstruction -> raised PVR -> acute RV strain -> (2) complement/histamine release -> further vasoconstriction/bronchoconstriction -> (3) monomer -> peripheral vasodilation + direct myocardial depression -> combined hypoxemia + hypotension +/- arrest.

Highest-risk moments: femoral canal reaming/broaching, cement insertion, prosthesis insertion, joint reduction.

1. Immediate recognition via temporal correlation with cementation

2. FiO2 100% immediately

3. IV fluid bolus + vasopressors (phenylephrine/noradrenaline) for hypotension; inotropes if RV dysfunction dominates

4. Communicate with surgeon, may pause the step

5. Treat as acute PE/RV strain physiologically; TEE if available

6. Full ACLS/CPR if Grade 3; prolonged resuscitation may be needed

7. Postoperative ICU monitoring, serial reassessment

State Donaldson's grading with exact numeric thresholds. Identify femoral canal venting and lavage as the two most effective preventive interventions; distinguish prevention from treatment clearly.

Severe thrombocytopenia (45,000/mm3) raises concern for spinal/epidural hematoma with neuraxial technique, while GA carries its own severe risks in pre-eclampsia (exaggerated pressor response, difficult airway, magnesium-NMB interaction). Fetal distress adds time pressure.

Decision in this case: with platelets at 45,000, most protocols favor GA due to unacceptable hematoma risk, despite GA's own risks - unless recent reliable coagulation profile supports individualized regional decision.

Target SBP <160, DBP <110 mmHg; avoid overly aggressive correction to preserve uteroplacental perfusion.

Treatment of toxicity: stop infusion, calcium gluconate 1g (10mL 10%) IV antidote, supportive ventilation.

PPH: oxytocin infusion first-line (slow, avoid bolus hypotension); avoid ergometrine (hypertensive effect); carboprost with caution; anticipate platelet transfusion need; escalate atony management per standard ladder.

Explicitly justify the GA-vs-regional choice using the given platelet count. Quote the magnesium toxicity staged levels with numbers and the calcium gluconate dose exactly.

Pheochromocytoma anesthesia swings from hypertensive crisis (induction, tumor handling, pneumoperitoneum) to potentially severe hypotension after venous ligation removes the catecholamine source. Adequate preoperative alpha-blockade is the single most important determinant of stability.

Beta-blockade added only AFTER adequate alpha-blockade (never start beta first - unopposed alpha stimulation -> crisis). Liberal volume/salt expansion preoperatively blunts post-excision hypotension.

High-risk triggers: laryngoscopy/intubation, pneumoperitoneum insufflation, direct tumor manipulation (highest risk), positioning changes.

Invasive arterial line before induction; central venous access; continuous ECG; communicate with surgeon before high-risk manipulation.

1. Anticipate - advance warning from surgeon, vasopressors drawn up

2. Volume loading before/during this phase

3. Stop/reduce vasodilator infusions immediately

4. Vasopressors: noradrenaline/phenylephrine first-line; vasopressin if refractory

5. Hydrocortisone if bilateral adrenalectomy

6. Monitor glucose closely (rebound hyperinsulinemia -> hypoglycemia)

7. Continue ICU monitoring 24-48h postoperatively

Quote Roizen's criteria by number - the single most commonly tested fact here. Structure the answer around the three hemodynamic phases and always mention post-excision hypoglycemia.